From a patient's point of view

P2.1

Patient-partners’ perspectives on involvement in a large multinational trial in Sjogren’s disease and suggestions for meaningfully involving patients in future research: A collaborative account by patient partners and the FOREUM study team

P2.2

Brochure about the psychological consequences of Sjögren’s disease

P2.3

Highlights of Patient-Driven & Patient-Involved Accomplishments Over 40 Years

P2.4

Assessment of Disease Activity between Patients and Physicians for Shared-Decision Making in Primary Sjögren Syndrome

P2.5

Associations among Patient Empowerment, Patient Engagement, Patient Activation and Clinical Manifestations in Primary Sjögren's Syndrome

P2.6

Disease perception in Sjogren Syndrome: is there any gender difference?

P2.7

Treatment options of oral dryness in Sjögren’s syndrome: a systematic review

P2.8

Sjögren’s disease and work: description of impacts from the perspective of occupational therapy

Glands and imaging

P2.9

Major Salivary Gland Ultrasound And Elastography Scores In A Cohort Of Indian Patients With Primary Sjogren’s Syndrome.

P2.10

Ultrasonography salivary glands in Sjögren's disease on the Russian cohort of patients

P2.11

Dynamics of US-changes in the structure of salivary glands with long-term rituximab therapy in patients with Sjögren's disease

P2.12

GLUT-1 expression in lymphocytes infiltrating Sjogren Disease salivary glands

P2.13

Frequency and impact of secondary Sjögren's Syndrome in connective tissue disease-related interstitial lung disease

P2.14

Are ultrasound salivary parenchymal abnormalities more severe in primary Sjögren patients with a longer disease duration? A cross-sectional international study.

P2.15

Performance of the salivary gland ultrasonography OMERACT score in the ACR-EULAR classification criteria for Sjögren’s disease

P2.16

The Use of Ga-68 PET/CT in the Evaluation of Salivary Glands in Sjögren's Syndrome

Pathogenetic aspects

P2.17

Extracellular Vesicles gene expression, DNA methylation, and immune cell trigger Sjögren’s syndrome: a multi-omics Mendelian randomization study

P2.18

IL-1 Pathway in Sjögren's Syndrome: The role in autoimmune epithelitis

P2.19

Targeted proteomics identifies differentially expressed proteins in primary Sjögren’s syndrome patients with lymphoma

P2.20

Prevalence and clinical significance of Autoantibodies to conventional Extractable Nuclear Antigens in anti-Ro/SSA seronegative patients with sicca complaints

P2.21

T follicular helper 1 cells in blood potentially mirror salivary gland-infiltrating T cells in primary Sjögren’s syndrome

P2.22

Analysis of TAM receptor expression in patients with Sjögren’s disease

P2.23

Association of the HLA class I and class II alleles with Sjogren’s syndrome and autoantibodies production.

P2.24

Role of m6A methylation of RNA in salivary gland epithelial cells: a new pathogenic pathway in Sjögren’s disease ?

P2.25

Leflunomide/hydroxychloroquine combination therapy targets disease-associated parotid and circulating transcriptomic networks reflecting B cell hyperactivity and virus/IFN activity in Sjogren's disease

P2.26

Potential value of the blood interferon signature in the diagnosis of pediatric-onset Sjögren’s disease patients

P2.27

Adherent salivary gland culture, often used to model salivary gland pathology in Sjögren’s Disease, contains more mesenchymal cells and a less diverse epithelial cell repertoire than salivary gland organoids

P2.28

Gut Microbiota changes in Sjogren’s Syndrome: Review of literature

P2.29

Identification of Sjögren’s Disease-Associated CD4+ T cell receptor (TCR) motifs and repertoire landscape through TCR deep sequencing

P2.30

Saliva and Plasma Metabolomics Profiling in Primary Sjögren's Syndrome Patients Using High-Resolution 1H 1D NMR Spectroscopy

P2.31

Unlocking the Viral Link: The Role of HDV in Sjogren’s Disease Pathogenesis

P2.32

Spatial insights into the salivary glands of patients with Sjogren’s Disease

P2.33

Elevated intracellular IFN signaling by T- and B cells is characteristic of anti-SSA positive asymptomatic women at risk for congenital heart block

P2.34

Deleting Mitochondrial Superoxide Dismutase 2 in Salivary Gland Ductal Epithelial Cells Recapitulates non-Sjögren's Sicca Syndrome.

P2.35

Mitochondrial dysfunction and increased mitochondrial superoxides in naïve CD4+ T-cells of primary Sjögren’s Syndrome

P2.36

Computational Systems Biology Approach to Unveil Molecular Interactions in Sjogren's Disease Pathogenesis

P2.37

Functional Evaluation of the PRDM1-ATG5 Risk Interval in Sjögren’s Disease

P2.38

Peptides of candidate Sjögren’s Disease autoantigens eluted from human salivary gland HLA-DR

Trials and tools

P2.39

Exploring the Therapeutic Potential and Mechanisms: Labial Gland Mesenchymal Stem Cells and Their Exosomes in Sjögren's Syndrome Treatment

P2.40

Impact of acupuncture on xerostomia and xerophthalmia in primary Sjögren’s disease: a randomized, double-blind clinical study

P2.41

The Use of “Black Magic” in Effectively Arresting Oral Decay in Patients with Sjögren’s Disease

P2.42

Development and validation of a nomogram for psychological stress in patients with primary Sjögren’s syndrome: a cross-sectional study

P2.43

Leflunomide is a safe and effective drug in patients with Sjögren's Syndrome with active systemic disease

P2.44

Prevalence of Tissue Specific Autoantibodies (TSAs) measured by newly developed chemiluminescence immunoassay (CLIA)

P2.45

Effect of Lymphoma Treatment Approaches on Hematologic Response and Autoimmune Disease Activity in Sjögren's Patients with Lymphoma

P2.46

Measurement of physical activity using mSQUASH: testing of face and construct validity in patients with Sjögren’s disease

P2.47

Mapping intra-oral ion concentrations in healthy volunteers

P2.48

Outcome measure in Sjögren’s disease randomized controlled trials: a systematic review

P2.49

Dose Dependent Modulation of Proteomic Signatures by Ianalumab in Patients with Sjögren’s Disease

P2.50

Effects of Daratumumab treatment on a single case of Sjögren’s disease complicated with linear IgA dermatosis

P2.51

Design of a global, phase 3, double-blind, placebo-controlled trial of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with active Sjögren’s disease

P2.52

Individuals at- risk for Sjögren’s syndrome show disease- characteristic clinical and immunological changes – results of the preSStige study

P2.53

Sjogren’s R Shiny apps for RNA sequencing analysis and biomarker discovery: make your graph from the two largest blood and salivary gland RNA-seq cohorts

P2.54

Assessment of Psychological Resilience for Developing Patient Empowerment Strategies in Patients with Primary Sjögren's Syndrome

P2.55

The Effects of Immunosupressive Therapy on Glandular Involvement in Patients with Primary Sjögren’s Syndrome

P2.56

Detection of anti-M3R antibodies in Sjögren’s Disease

Extra-glandular involvement

P2.57

Pulmonary involvement secondary to primary Sjögren's Syndrome: monocentric experience from a tertiary care referral hospital

P2.58

Gastroesophageal reflux disease (GERD) modifies the expression of dryness in patients with Sjogren's disease (SD) and nonautoimmune sicca syndrome (nonautoimmSicca)

P2.59

What is the impact of comorbidity in Sjögren’s patients with an unacceptable symptom burden and limited extra-glandular disease activity?

P2.60

Respiratory Symptoms & Disease In Sjögren’s: Patient Experience & Impact On Quality Of Life

P2.61

Distinctieve extra-glandular and immunological features in youth-onset Primary sjogren's syndrome: A clinical Insight

P2.62

Co-Occurrence & Impact of POTS on Quality of Life in Sjögren's

P2.63

Assessment of small airways dysfunction in primary Sjögren’s Disease with different contemporary pulmonary function tests

P2.64

Prevalence of malignancies, besides lymphoma, in patients with Sjogren's syndrome: 10 years of experience in an Italian cohort

P2.65

Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies

P2.66

Prevalence Of Myositis In Primary Sjogren’s Syndrome Patients In A Multi Centre Indian Cohort

P2.67

Older age at Sjögren’s Disease diagnosis is an independent predictor of lymphoma in a cohort with a lower prevalence of hematological malignancy — data from PORTRESS, the Portuguese Sjögren’s Disease registry

P2.68

Raynaud's Phenomenon in Sjögren's Syndrome: A Monocentric Italian Cross-Sectional Study

P2.69

Glandular and Extraglandular Damage is Highly Prevalent in Patients with Sjögren's Disease and is Associated with Age, Disease Duration, Rheumatoid Factor and Glandular Enlargement

P2.70

Elevated Beta-2 microglobulin levels at diagnosis are related to systemic involvement development and survival in patients with Sjogren’s syndrome

P2.71

Interstitial lung disease as an early feature in Sjogren's syndrome – experience of a tertiary centre

Classification and stratification

P2.72

Decoding the Autoantibody Landscape in Sjogren’s Disease (SjD) by Integration with Salivary Gene Expression.

P2.73

Prevalence of renal manifestation and its association with symptoms, disease activity, damage and quality of life in Sjogren's Disease: data from Brazilian Registry of Sjogren's Disease (REBRAS)

P2.74

Common systemic involvement and worsening disease burden in patients with Sjögren’s disease: data from PORTRESS, the Portuguese registry of Sjögren’s Disease

P2.75

Addressing the need for the early detection of mucosa-associated lymphoid tissue lymphoma (MALTL) in primary Sjögren's Syndrome through data augmentation

P2.76

Anti-citrullinated protein antibodies in Sjögren’s syndrome define a subset of patients with lower B cell activation markers and higher risk of lung involvement and articular damage

P2.77

Predictors and associated factors with fatigue in Sjögren's Disease: data from the Brazilian Sjögren's Disease registry (REBRAS)

P2.78

The relevance of icos expression on CD4+ T Cells in Sjögren's Disease: a diagnostic perspective

P2.79

Relationships between cell subpopulations of inflammatory infiltrates in labial salivary glands and clinical, immunological parameters in patient with primary Sjogren’s syndrome

P2.80

Socio-demographic and phenotypic differences between the Brazilian and Portuguese populations: Data from the Brazilian registry of Sjögren's Disease (REBRAS) and the Portuguese registry of Sjögren's Disease (PORTRESS-REUMA.PT)

P2.81

Characteristics of lymphoproliferative diseases in primary Sjogren’s syndrome.

P2.82

Sjögren’s disease activity and clinical characteristics of patients with seropositive and seronegative anti-SSA/Ro and anti-SSB/La antibody test results

P2.83

Association of Sjögren’s disease activity (ClinESSDAI) and symptom burden (ESSPRI) with patient-reported outcome measures

P2.84

Gender-Specific Clinical and Immunologic Profiles in Primary Sjögren’s Syndrome: A Comparative Study in China